Published in J Virol on January 24, 2007
Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog (2009) 2.34
Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology (2007) 1.46
Synchronous infection of SIV and HIV in vitro for virology, immunology and vaccine-related studies. Nat Protoc (2010) 1.08
Monitoring early fusion dynamics of human immunodeficiency virus type 1 at single-molecule resolution. J Virol (2008) 0.97
Role of gp120 trimerization on HIV binding elucidated with Brownian adhesive dynamics. Biophys J (2008) 0.83
Entry kinetics and cell-cell transmission of surface-bound retroviral vector particles. J Gene Med (2010) 0.82
Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum. PLoS Pathog (2013) 0.80
Activation and Inactivation of Primary Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Trimers by CD4-Mimetic Compounds. J Virol (2016) 0.79
Cell-cell transmission of VSV-G pseudotyped lentivector particles. PLoS One (2013) 0.78
Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion. PLoS Comput Biol (2014) 0.75
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 13.54
The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 12.44
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol (1997) 12.11
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol (2000) 8.62
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell (1996) 6.52
Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology (1992) 5.64
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med (1998) 4.77
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A (2002) 4.48
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A (1999) 4.46
A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1994) 3.97
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol (1993) 3.95
Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci U S A (1994) 3.33
The antiviral activity of antibodies in vitro and in vivo. Adv Immunol (2001) 3.29
Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol (1998) 3.23
Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol (1998) 3.11
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology (1995) 3.06
HIV-1 membrane fusion: targets of opportunity. J Cell Biol (2000) 2.84
Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. J Virol (2000) 2.80
Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med (1997) 2.31
Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol (2003) 2.31
Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol (2002) 2.21
HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell (2003) 2.18
Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol (2005) 2.05
The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J Virol (2000) 2.03
Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol (2002) 1.79
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol (2005) 1.65
Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J (2004) 1.61
Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol (2004) 1.58
Kinetic dependence to HIV-1 entry inhibition. J Biol Chem (2006) 1.56
Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies (2005) 1.46
Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J Virol (2002) 1.30
Mechanisms of transmissible gastroenteritis coronavirus neutralization. Virology (1990) 1.21
Toward a more accurate quantitation of the activity of recombinant retroviruses: alternatives to titer and multiplicity of infection. J Virol (2000) 1.14
Synchronized infection of cell cultures by magnetically controlled virus. J Virol (2005) 1.14
Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. J Virol (1996) 1.07
Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition. J Virol (2001) 0.97
Potent broad cross-neutralizing sera inhibit attachment of primary HIV-1 isolates (groups M and O) to peripheral blood mononuclear cells. Virology (2001) 0.94
Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies. Eur J Biochem (2001) 0.91
Cellular factors influence the binding of HIV type 1 to cells. AIDS Res Hum Retroviruses (2002) 0.86
Postattachment neutralization of a primary strain of HIV type 1 in peripheral blood mononuclear cells is mediated by CD4-specific antibodies but not by a glycoprotein 120-specific antibody that gives potent standard neutralization. AIDS Res Hum Retroviruses (2001) 0.82
Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol (2005) 3.34
Lyme neuroborreliosis: infection, immunity, and inflammation. Lancet Neurol (2007) 2.42
Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. J Virol (2004) 1.89
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther (2005) 1.85
Neurological picture. Herpes zoster duplex bilateralis. J Neurol Neurosurg Psychiatry (2007) 1.79
Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. J Virol (2004) 1.72
Steroids in bacterial meningitis: yes. J Neural Transm (Vienna) (2012) 1.48
Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine (2005) 1.23
Synchronized infection of cell cultures by magnetically controlled virus. J Virol (2005) 1.14
Past as prologue: delayed stroke as a parainfectious process of bacterial meningitis? Neurology (2009) 1.13
Presence of HSV-1 immediate early genes and clonally expanded T-cells with a memory effector phenotype in human trigeminal ganglia. Brain Pathol (2007) 1.11
Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol (2005) 1.11
Recent issues in herpes simplex encephalitis. J Neurovirol (2013) 1.08
Creutzfeldt-Jakob disease. JAMA Neurol (2013) 1.06
Infectious causes of multiple sclerosis. Lancet Neurol (2006) 1.04
Gene transfer mediated by different viral vectors following direct cannulation of mouse submandibular salivary glands. Eur J Oral Sci (2002) 0.98
Chronic intracranial hypertension with unexplained cerebrospinal fluid pleocytosis. J Neuroophthalmol (2004) 0.97
Modeling of human cytomegalovirus maternal-fetal transmission in a novel decidual organ culture. J Virol (2011) 0.96
Recurrence of Sydenham chorea: implications for pathogenesis. Arch Neurol (2004) 0.96
Acute bilateral paramedian thalamic infarcts after occlusion of the artery of Percheron. Neurology (2006) 0.94
Neurological abnormalities associated with celiac disease. J Neurol (2004) 0.93
The multiple sclerosis severity score (MSSS) predicts disease severity over time. J Neurol Sci (2009) 0.92
Neurotropism of herpes simplex virus type 1 in brain organ cultures. J Gen Virol (2006) 0.92
The latency-associated gene of herpes simplex virus type 1 (HSV-1) interferes with superinfection by HSV-1. J Neurovirol (2002) 0.91
Herpes simplex virus type 1 preferentially targets human colon carcinoma: role of extracellular matrix. J Virol (2007) 0.91
Family with inflammatory demyelinating polyneuropathy and the HNPP 17p12 deletion. Am J Med Genet (2002) 0.90
Delayed cerebral thrombosis after initial good recovery from pneumococcal meningitis: past as prologue: delayed stroke as a parainfectious process of bacterial meningitis? Neurology (2010) 0.88
Prolonged transgene expression in murine salivary glands following non-primate lentiviral vector transduction. Mol Ther (2005) 0.86
Statins lower the risk of developing Alzheimer's disease by limiting lipid raft endocytosis and decreasing the neuronal spread of Herpes simplex virus type 1. Med Hypotheses (2005) 0.85
Models of vertical cytomegalovirus (CMV) transmission and pathogenesis. Semin Immunopathol (2014) 0.84
Myasthenia gravis in the elderly. J Neurol Sci (2012) 0.83
Restrictions that control herpes simplex virus type 1 infection in mouse brain ex vivo. J Gen Virol (2011) 0.83
Primary brain T-cell lymphoma in an HTLV-1 serologically positive male. J Neurol Sci (2011) 0.83
Viral mediated gene transfer to sprouting blood vessels during angiogenesis. J Virol Methods (2002) 0.83
Treating post Lyme disease: trying to solve one equation with too many unknowns. Neurology (2003) 0.82
PML: underdiagnosed in MS patients on natalizumab. Lancet Neurol (2010) 0.81
Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins. Mol Ther (2005) 0.81
Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias. J Neural Transm (Vienna) (2012) 0.81
Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity. J Gen Virol (2012) 0.80
Reengineering salivary gland cells to enhance protein secretion for use in developing artificial salivary gland device. Tissue Eng (2007) 0.80
Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity. J Mol Neurosci (2013) 0.80
Replication of HIV-1 deleted Nef mutants in chronically immune activated human T cells. Virology (2002) 0.80
Involvement of cellular death signals in the reactivation of herpes simplex virus type 1 and lambda bacteriophage from a latent state. J Theor Biol (2005) 0.80
Transgenic mouse with the herpes simplex virus type 1 latency-associated gene: expression and function of the transgene. J Virol (2003) 0.80
Nonconvulsive status epilepticus in older people: a diagnostic challenge and a treatable condition. J Am Geriatr Soc (2007) 0.79
Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients. J Neurol (2008) 0.79
Tropism of lentiviral vectors in skin tissue. Hum Gene Ther (2008) 0.79
Post infectious CNS disorders: towards a unified approach. J Neurol (2010) 0.78
The protective effect of risk factors against stroke severity. J Neurol Sci (2008) 0.78
Plagiarism. Trans R Soc Trop Med Hyg (2010) 0.78
On human disease and animal models. Ann Neurol (2011) 0.77
Nocturnal carbon dioxide monitoring in patients with idiopathic intracranial hypertension. Clin Neurol Neurosurg (2013) 0.77
Integrated strategy for the production of therapeutic retroviral vectors. Hum Gene Ther (2011) 0.77
Infant lungs are preferentially infected by adenovirus and herpes simplex virus type 1 vectors: role of the tissue mesenchymal cells. J Gene Med (2011) 0.77
Gene delivery by viral vectors in primary cultures of lacrimal gland tissue. Invest Ophthalmol Vis Sci (2003) 0.76
Different modes of herpes simplex virus type 1 spread in brain and skin tissues. J Neurovirol (2014) 0.76
Molecular characterization of a human monoclonal antibody that interacts with a sulfated tyrosine-containing epitope of the GPIb receptor and inhibits platelet functions. Mol Immunol (2005) 0.76
Psychiatric side effects of acute high-dose corticosteroid therapy in neurological conditions. Int Clin Psychopharmacol (2016) 0.76
The possible risk for strokes complicating cardiac surgery in patients with intraoperative hypothermia. Cerebrovasc Dis (2010) 0.76
Characterization of factors that determine lentiviral vector tropism in skin tissue using an ex vivo model. J Gene Med (2011) 0.76
Quo vadis multiple sclerosis? Inflammopharmacology (2010) 0.75
Prior TIA, lipid-lowering drug use, and physical activity decrease ischemic stroke severity. Neurology (2007) 0.75
Quantitative risk-benefit analysis of natalizumab. Neurology (2009) 0.75
Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology (2002) 0.75
Coital headaches induced by amiodarone. Neurology (2002) 0.75
The "one virus, one disease" model of multiple sclerosis is too constraining. Ann Neurol (2007) 0.75
Smoking is a risk factor for multiple sclerosis. Neurology (2004) 0.75
The occurrence of Guillain-Barré syndrome within families. Neurology (2005) 0.75
Re: Recanalization after intravenous thrombolysis: does a recanalization time window exist? Neurology (2008) 0.75
Herpes zoster duplex bilateralis. BMJ Case Rep (2009) 0.75
Biopump: Autologous skin-derived micro-organ genetically engineered to provide sustained continuous secretion of therapeutic proteins. Dermatol Ther (2012) 0.75
The relatively good outcome of cerebellum-brainstem ischemic strokes. Eur Neurol (2012) 0.75
Neurological deficits in patients with celiac disease. Arch Neurol (2002) 0.75
Complete mitochondrial DNA sequence analysis in a family with early-onset dystonia and optic atrophy. Mov Disord (2004) 0.75
Acute confusion and seizures in a 63-year-old woman. J Clin Neurosci (2013) 0.75
Intracellular expression of a functional short peptide confers resistance to apoptosis. Exp Cell Res (2003) 0.75
Lack of migraine in headaches of familial dysautonomia patients. J Neural Transm (Vienna) (2012) 0.75
Unsung hero Robert C. Gallo. Science (2009) 0.75
A 66-year-old patient with progressive left hemiparesis: question. J Clin Neurosci (2014) 0.75
Unusual and benign course of idiopathic facial diplegia. J Clin Neurosci (2013) 0.75